Gabapentin Capsule
Product Images NDC 71335-1484

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-1484). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Gabapentin Fig1)

An illustrated formula for calculating creatinine clearance (CLCr), showing how to use age, weight, serum creatinine levels, and a gender adjustment factor (0.85 for females) in the equation.*

FDA Label Image

Figure 1 (Gabapentin Fig2)

A line graph showing mean pain scores over an 8-week period separated into a 4-week dose titration period and a 4-week fixed dose period. Two lines represent placebo and gabapentin 3600 mg/day, with gabapentin showing a greater reduction in mean pain score compared to placebo over time.*

FDA Label Image

Figure 2 (Gabapentin Fig3)

A line graph depicting mean pain score over 7 weeks, comparing placebo to Gabapentin at doses of 1800 mg/day and 2400 mg/day. The x-axis represents weeks, while the y-axis indicates mean pain score, showing a decrease in pain score with Gabapentin compared to placebo during a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure 3 (Gabapentin Fig4)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing two studies. Each study compares placebo (PBO) with gabapentin (GBP) at different dosages. Study 1 shows 12% for placebo and 29% for GBP 3600 mg, while Study 2 shows 14% for placebo and 32% for GBP 1800 mg and 34% for GBP 2400 mg. Significance levels are indicated with ** p < 0.01 and *** p < 0.001.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

A scatter plot showing percentage differences on the y-axis and daily dose in mg on the x-axis. The graph compares three studies (a, b, c) at daily doses 600 mg, 900 mg, 1200 mg, and 1800 mg, with data points labeled by study and marked by different symbols. Study a is shown with filled squares, study b with gray-filled squares, and study c with open squares.*

FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical structure of Gabapentin showing a cyclohexane ring attached to both an amino group (CH2NH2) and a carboxylic acid group (CH2CO2H).*

FDA Label Image

Label Image (Lbl713351484)

Gabapentin 100 mg (CV) capsule label indicates the drug is packaged by Bryant Ranch Prepack in Burbank, CA. The label includes storage instructions at 20°-25°C (68°-77°F), a warning about possible dizziness, and a note to keep drugs out of children's reach. It compares to Neurontin 100 mg capsules and shows a count of 90 capsules. The NDC number is 71335-1484.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.